Novartis Ag (NVS) Change in Receivables (2022 - 2026)
Novartis Ag's (NVS) quarterly Change in Receivables came in at -$504.0 million in Q1 2026, up 45.22% quarter-over-quarter from -$920.0 million in Q1 2024.
Novartis Ag (NVS) Change in Receivables (2022 - 2026) Analysis & Trends
Novartis Ag has disclosed Change in Receivables across 4 years of filings, most recently posting -$504.0 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -504.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -504.00 Mn |
| Mar 31, 2026 | -504.00 Mn |
| Mar 31, 2024 | -920.00 Mn |
| Mar 31, 2024 | -920.00 Mn |
| Mar 31, 2023 | -850.00 Mn |
| Mar 31, 2023 | -850.00 Mn |
| Mar 31, 2022 | -496.00 Mn |
| Mar 31, 2022 | -496.00 Mn |